Invitae Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NVTA research report →
Companywww.invitae.com
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners.
- CEO
- Kenneth D. Knight
- IPO
- 2015
- Employees
- 1,700
- HQ
- San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $5.44M
- P/E
- -0.00
- P/S
- 0.01
- P/B
- 0.04
- EV/EBITDA
- -0.52
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 19.18%
- Op Margin
- -138.34%
- Net Margin
- -601.64%
- ROE
- -201.69%
- ROIC
- -37.74%
Growth & Income
- Revenue
- $516.30M · 12.13%
- Net Income
- $-3,106,293,000 · -719.59%
- EPS
- $-13.18 · -632.22%
- Op Income
- $-714,236,000
- FCF YoY
- 11.11%
Performance & Tape
- 52W High
- $2.34
- 52W Low
- $0.01
- 50D MA
- $0.46
- 200D MA
- $0.84
- Beta
- 1.59
- Avg Volume
- 12.70M
Get TickerSpark's AI analysis on NVTA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 20, 23 | Nussbaum Robert L | other | 17,404 |
| Dec 20, 23 | Brida Thomas | other | 17,404 |
| Nov 13, 23 | Sholehvar David | other | 850,000 |
| Nov 13, 23 | Sholehvar David | other | 0 |
| Oct 18, 23 | Brida Thomas | other | 229,500 |
| Oct 2, 23 | Schrank Ana J. | other | 850,000 |
| Oct 2, 23 | Schrank Ana J. | other | 0 |
| Sep 23, 23 | Guigley Robert M. | other | 850,000 |
| Sep 5, 23 | Guigley Robert M. | other | 0 |
| Aug 14, 23 | Dickey Robert IV | other | 0 |
Our NVTA Coverage
We haven't published any research on NVTA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NVTA Report →